256 related articles for article (PubMed ID: 17497996)
21. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study.
Visich JE; Zuckerman LA; Butine MD; Gunewardena KA; Wild R; Morton KM; Reynolds TC
Thromb Haemost; 2005 Oct; 94(4):802-7. PubMed ID: 16270634
[TBL] [Abstract][Full Text] [Related]
22. Phenotype-genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations.
Ivaskevicius V; Windyga J; Baran B; Schroeder V; Junen J; Bykowska K; Seifried E; Kohler HP; Oldenburg J
Haemophilia; 2007 Sep; 13(5):649-57. PubMed ID: 17880458
[TBL] [Abstract][Full Text] [Related]
23. The effect of different apheresis modalities on coagulation factor XIII level during antibody removal in ABO-blood type incompatible living related renal transplantation.
Hanafusa N; Hamasaki Y; Kawarasaki H; Kido R; Shibagaki Y; Ishikawa A; Enomoto Y; Fujita T; Noiri E; Nangaku M
Transfus Apher Sci; 2013 Oct; 49(2):254-8. PubMed ID: 23827327
[TBL] [Abstract][Full Text] [Related]
24. Factor XIII and venous thromboembolism.
Bereczky Z; Muszbek L
Semin Thromb Hemost; 2011 Apr; 37(3):305-14. PubMed ID: 21455864
[TBL] [Abstract][Full Text] [Related]
25. Occurrence and recurrence of spontaneous chronic subdural haematoma is associated with a factor XIII deficiency.
Bosche B; Molcanyi M; Noll T; Kochanek M; Kraus B; Rieger B; El Majdoub F; Dohmen C; Löhr M; Goldbrunner R; Brinker G
Clin Neurol Neurosurg; 2013 Jan; 115(1):13-8. PubMed ID: 22541133
[TBL] [Abstract][Full Text] [Related]
26. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome.
Okamiya S; Ogino M; Ogino Y; Irie S; Kanazawa N; Saito T; Sakai F
Ther Apher Dial; 2004 Jun; 8(3):248-53. PubMed ID: 15154879
[TBL] [Abstract][Full Text] [Related]
27. A patient whose factor XIII level was decreased by double filtrate plasmapheresis and successfully recovered by infusion of factor XIII concentrate.
Hanafusa N; Aozasa N; Fujita T
Ther Apher Dial; 2010 Aug; 14(4):432-3. PubMed ID: 20649765
[No Abstract] [Full Text] [Related]
28. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction.
Nahrendorf M; Aikawa E; Figueiredo JL; Stangenberg L; van den Borne SW; Blankesteijn WM; Sosnovik DE; Jaffer FA; Tung CH; Weissleder R
Eur Heart J; 2008 Feb; 29(4):445-54. PubMed ID: 18276618
[TBL] [Abstract][Full Text] [Related]
29. Cleavage of factor XIII by human neutrophil elastase results in a novel active truncated form of factor XIII A subunit.
Bagoly Z; Fazakas F; Komáromi I; Haramura G; Tóth E; Muszbek L
Thromb Haemost; 2008 Apr; 99(4):668-74. PubMed ID: 18392324
[TBL] [Abstract][Full Text] [Related]
30. Acquired plasma factor XIII deficiencies.
Tosetto A; Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):5-10. PubMed ID: 8039759
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Factor XIII.
Muszbek L; Katona É; Kerényi A
Methods Mol Biol; 2017; 1646():277-293. PubMed ID: 28804836
[TBL] [Abstract][Full Text] [Related]
32. Rapid determination of blood coagulation factor XIII activity using protein arrays for serodiagnosis of human plasma.
Kwon MH; Kong DH; Jung SH; Suh IB; Kim YM; Ha KS
Anal Chem; 2011 Mar; 83(6):2317-23. PubMed ID: 21323342
[TBL] [Abstract][Full Text] [Related]
33. Factor XIII subunits in human tears; their highly elevated levels following penetrating keratoplasty.
Orosz ZZ; Katona É; Facskó A; Módis L; Muszbek L; Berta A
Clin Chim Acta; 2011 Jan; 412(3-4):271-6. PubMed ID: 20974119
[TBL] [Abstract][Full Text] [Related]
34. Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics.
Nielsen VG; Kirklin JK; Hoogendoorn H; Ellis TC; Holman WL
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):145-50. PubMed ID: 17287631
[TBL] [Abstract][Full Text] [Related]
35. Factor XIII and atherothrombotic diseases.
Muszbek L; Bereczky Z; Bagoly Z; Shemirani AH; Katona E
Semin Thromb Hemost; 2010 Feb; 36(1):18-33. PubMed ID: 20391293
[TBL] [Abstract][Full Text] [Related]
36. Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency.
Peyvandi F; Tagliabue L; Menegatti M; Karimi M; Komáromi I; Katona E; Muszbek L; Mannucci PM
Hum Mutat; 2004 Jan; 23(1):98. PubMed ID: 14695539
[TBL] [Abstract][Full Text] [Related]
37. Successful preoperative treatment of a Graves' disease patient with agranulocytosis and hemophagocytosis using double filtration plasmapheresis.
Lew WH; Chang CJ; Lin JD; Cheng CY; Chen YK; Lee TI
J Clin Apher; 2011; 26(3):159-61. PubMed ID: 21268097
[TBL] [Abstract][Full Text] [Related]
38. A case report of efficiency of double filtration plasmapheresis in treatment of Goodpasture's syndrome.
Hajime N; Michiko A; Atsunori K; Tatsuo K; Yuko N; Naoki O; Katsuhiko S
Ther Apher Dial; 2009 Aug; 13(4):373-7. PubMed ID: 19695077
[TBL] [Abstract][Full Text] [Related]
39. Factor XIII deficiency in children--clinical presentation and outcome.
Fadoo Z; Saleem AF
J Coll Physicians Surg Pak; 2008 Sep; 18(9):565-8. PubMed ID: 18803895
[TBL] [Abstract][Full Text] [Related]
40. Comparison of three modalities of plasmapheresis on coagulation: Centrifugal, single-membrane filtration, and double-filtration plasmapheresis.
Marlu R; Naciri Bennani H; Seyve L; Noble J; Chevallier E; Motte L; Imerzoukene F; Bugnazet M; Christophe M; Malvezzi P; Jouve T; Rostaing L
J Clin Apher; 2021 Jun; 36(3):408-419. PubMed ID: 33506958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
